DC-SIGN polymorphisms are associated to type 1 diabetes mellitus

Silva, Ronaldo Celerino da; Tavares, Nathalia de Alencar Cunha; Moura, Ronald; Coelho, Antônio Victor Campos; Guimarães, Rafael Lima; Araújo, Jacqueline; Crovella, Sérgio; Brandão, Lucas André Cavalcanti; Silva, Jaqueline de Azevêdo

doi:10.1016/j.imbio.2014.07.011

Cited by 6 publications

(2 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As a receptor expressed on DCs, CD209 contributes to stabilizing the interaction between dendritic cells and T cells 24 . CD209 promoter polymorphisms increase the susceptibility to autoimmunity, which has been reported to correlate with RA and type 1 diabetes 20,25 …”

Section: Discussionmentioning

confidence: 99%

“…These infections may also contribute to the development of RA 19 . In contrast to its pathogenic role in infectious diseases, recent studies revealed that two SNPs in the promoter region of CD209 (rs4804803 and rs735239) showed protective effects against the development of type 1 diabetes, a kind of immune‐related disease 20 . The exact mechanism is still obscure.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A novel CD209 polymorphism is associated with rheumatoid arthritis patients in Taiwan

Chan

Wang

Lin

et al. 2021

Clinical Laboratory Analysis

View full text Add to dashboard Cite

Single nucleotide polymorphisms (SNPs) in the promoter region of CD209 (cluster of differentiation 209) may influence expression levels, and higher expression of CD209 on immune cells correlate with severity of cartilage destruction in patients with rheumatoid arthritis (RA). Due to the lack of a comprehensive study, this study aimed to investigate the CD209 promoter variants and haplotypes in a Taiwanese population and the association with RA development. Deoxyribonucleic acid (DNA) of peripheral blood mononuclear cells from 126 RA patients and 124 healthy controls was purified, and the CD209 gene promoter was amplified by polymerase chain reaction and analyzed by Sanger sequencing. Results showed that a novel variant −96C>A polymorphism in CD209 promoter was identified in the Taiwanese population, and the frequency was significantly higher in RA patients than in controls (11.51% vs. 2.42%, P < .0001). The odds ratio (OR) for the development of RA was 5.88 (95% CI 2.35–14.74, P < .0001). Other known variants were also evaluated; for instance, −1180 T/T (rs7359874) was increased in RA patients, and the OR for the development of RA was 3.26, 95% CI 0.85–12.52, P = .07). Besides, the haplotype frequencies were calculated; −1180A‐939C‐871 T‐336 T‐139 T‐96A and −1180 T‐939 T‐871C‐336 T‐139C‐96A were increased in RA patients (P = .004 and 0.05, respectively). In summary, CD209‐96A variant could be an important factor for the development of RA in the Taiwanese population.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%